Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 757-1, Asahimachidori, Chuo-ku, Niigata, 951-8510, Japan.
Digestive Diseases Center, Showa University Koto Toyosu Hospital, Tokyo, Japan.
J Gastroenterol. 2021 Apr;56(4):360-370. doi: 10.1007/s00535-021-01763-6. Epub 2021 Feb 4.
Achalasia has been reported to be associated with esophageal cancers (ECs). However, owing to the rarity of achalasia, details of achalasia-related ECs are not well investigated.
The incidence of ECs in Japanese patients with achalasia and achalasia-related esophageal motility disorders (EMDs) was estimated, and risk factors for achalasia-related ECs were determined. Characteristics of ECs and treatment courses were also analyzed.
Between 2010 and 2019, 2714 Japanese patients with achalasia and achalasia-related EMDs were recorded in 7 high-volume centers; 24 patients (21 men, 3 women) developed ECs. The incidence of ECs was estimated at 0.078 and 0.28 per 100 person-years from the onset and the diagnosis of disease, respectively. Kaplan-Meier estimate suggested that, in addition to a long history of achalasia, advanced age, male sex, and regular alcohol consumption were statistically significant risk factors for EC development. A prevalence of 40 ECs (12.5% multiple lesions, and 22.7% metachronal lesions) was also noted, predominantly distributed over the thoracic esophagus. All were histologically diagnosed as squamous cell carcinoma. Superficial ECs were successfully treated with endoscopic treatment in all cases, except one. Achalasia-related Barret esophagus was extremely rare, and Barret adenocarcinoma was not detected in our cohort.
The high relative risk of ECs was clarified in Japanese achalasia patients, although the absolute risk remained low. Therefore, surveillance endoscopy may be recommended in limited patients with several aforementioned risk factors determined. Superficial cancer can be treated with endoscopic treatment. Multiple and metachronal ECs should be screened.
贲门失弛缓症与食管癌(ECs)有关。然而,由于贲门失弛缓症的罕见性,贲门失弛缓症相关食管癌的细节尚未得到充分研究。
估计了日本贲门失弛缓症和贲门失弛缓症相关食管动力障碍(EMD)患者中食管癌的发病率,并确定了贲门失弛缓症相关食管癌的危险因素。还分析了食管癌的特征和治疗过程。
在 2010 年至 2019 年间,7 家大容量中心共记录了 2714 例日本贲门失弛缓症和贲门失弛缓症相关 EMD 患者;24 例(21 名男性,3 名女性)发生了食管癌。从发病和诊断开始,食管癌的发病率估计分别为 0.078 和 0.28 每 100 人年。Kaplan-Meier 估计表明,除了贲门失弛缓症病史长外,年龄较大、男性和定期饮酒也是食管癌发展的统计学显著危险因素。还注意到 40 例食管癌(12.5%多发性病变,22.7%异时性病变)的患病率,主要分布在胸段食管。所有病例均经组织学诊断为鳞状细胞癌。除 1 例外,所有浅表性食管癌均通过内镜治疗成功治疗。贲门失弛缓症相关的 Barrett 食管非常罕见,我们的队列中未检测到 Barrett 腺癌。
在日本贲门失弛缓症患者中明确了食管癌的高相对风险,尽管绝对风险仍然较低。因此,在确定了上述几个危险因素的有限患者中,可能需要进行监测性内镜检查。浅表性癌症可以通过内镜治疗进行治疗。应筛查多发性和异时性食管癌。